Johnson & Johnson has announced that it is separating its company’s consumer health business, creating a new publicly traded company. The company is targeting the completion of the planned separation in 18-24 months.

According to the company, the planned separation would create two global leaders that are better positioned to deliver improved health outcomes for patients and consumers through innovation, pursue more targeted business strategies and accelerate growth.

The new consumer health company would be a global consumer health company, featuring brands such as Neutrogena, Aveeno, Tylenol, Listerine, Johnson’s, and Band-Aid and leading positions in self-care (OTC), skin health and essential health, which include baby care, feminine care, wound care and oral health.

The updated Johnson & Johnson would continue to build on its offering of health care R&D and innovation with its portfolio entailing pharmaceutical and medical device capabilities focused on advancing standard care.

Read more…

By Jacquelyn Schlabach – Nov 12th, 2021